Acumen Pharmaceuticals Confirms Phase 2 Sabirnetug Trial on Track, Data by Late 2026
Acumen Pharmaceuticals said its Phase 2 ALTITUDE-AD trial of sabirnetug remains on track with top-line data expected late 2026. The Q1 call highlighted continued advancement of its broader Alzheimer’s disease pipeline as the company readies for late-stage development.
1. Q1 2026 Operational Highlights
During the Q1 earnings call, the company reiterated that its lead asset sabirnetug continues to meet enrollment and safety milestones in its Phase 2 ALTITUDE-AD trial. Management emphasized that site activation and patient recruitment are proceeding according to schedule.
2. ALTITUDE-AD Phase 2 Sabirnetug Trial
The ALTITUDE-AD study is designed to assess cognitive endpoints and biomarker changes in patients with early Alzheimer’s disease. Top-line results are slated for release in late 2026, setting the stage for potential late-stage trial initiation.
3. Broader Alzheimer’s Pipeline Progress
Beyond sabirnetug, Acumen confirmed ongoing preclinical work on additional small-molecule candidates targeting amyloid and tau pathways. The company plans to nominate a second clinical candidate by mid-2026.
4. Upcoming Catalysts and Financial Outlook
Key upcoming catalysts include the late-2026 sabirnetug data readout and a mid-year candidate selection for its second program. These events are critical for determining future financing needs and partnership opportunities.